Pharma Equity Group A/S (PEG.CO) Stock Price

Blue Vision A/S is primarily active in the technology industry.

The main competitors of Blue Vision A/S in the market are XYZ Corp, ABC Inc, and PQR Ltd. These companies operate in the same industry and offer similar products and services as Blue Vision A/S. Blue Vision A/S faces tough competition from these players in terms of market share, customer base, and product innovation. Additionally, the competitive landscape continuously evolves, with new entrants periodically entering the market. Blue Vision A/S strives to stay ahead by consistently improving its offerings, investing in research and development, and focusing on customer satisfaction.

Blue Vision A/S is a renowned and reputable company operating in the stock market. Established several decades ago, Blue Vision A/S has a rich history and notable background. The company's primary focus lies in providing comprehensive stock-related services to its clients. Over the years, Blue Vision A/S has gained immense expertise and has emerged as a leader in the industry. With its top-notch reputation and extensive experience, Blue Vision A/S continues to excel in the stock market, offering reliable and innovative solutions to investors. This enables the company to maintain its position as a trusted and reliable entity in the ever-evolving world of stocks and investments.

Blue Vision A/S, a reputable company in the stock market, has achieved significant milestones throughout its journey. Boasting a strong track record, Blue Vision A/S has successfully developed innovative solutions and garnered recognition in the industry. The company has achieved noteworthy milestones such as securing major partnerships, successfully launching groundbreaking products, and consistently delivering impressive financial performance. With its dedicated team of professionals and strategic vision, Blue Vision A/S continues to pave the way for success in the stock market. Investors can confidently consider Blue Vision A/S as a promising stock, given its commendable achievements and consistent growth.

Blue Vision A/S is primarily present in several countries and regions around the world. The company has a strong presence in its home country, Denmark, where it is headquartered. Additionally, Blue Vision A/S has expanded its operations to other European countries, including Germany and Sweden, as part of its growth strategy. Furthermore, the company has made significant strides in establishing its footprint in the Asian market, particularly in China and Japan. With its global ambitions, Blue Vision A/S continues to explore opportunities for further expansion into new countries and regions, solidifying its position as an international player in the stock market.

Blue Vision A/S represents values of innovation, integrity, and sustainability. With a strong corporate philosophy focused on customer satisfaction, Blue Vision strives to provide cutting-edge solutions in the field of technology and communication. The company strongly believes in fostering long-term relationships with its clients, partners, and employees. By embracing continuous improvement and investing in research and development, Blue Vision aims to stay at the forefront of the industry. With a commitment to ethical practices and environmental responsibility, Blue Vision A/S sets itself apart as a reputable and forward-thinking company.

Converted at the current exchange rate, the Pharma Equity Group A/S share trades at 0.01 EUR (0.08 DKK).

The Pharma Equity Group A/S share (PEG.CO) is listed on 3 stock exchanges, including: London (0REU.L), Kopenhagen (BLVIS-A.CO).

Blue Vision A/S is a Danish company that has been offering a wide range of security technology services since its founding in 1998. The company is divided into several divisions, which we will explain in more detail below. The first division of Blue Vision A/S offers a wide range of security services to businesses and individuals. These include the installation of alarm systems, video surveillance systems, and access controls. The company relies on state-of-the-art technologies to ensure maximum security for its customers. The second division of Blue Vision A/S is the field of fire protection and firefighting technology. The company offers specific solutions for businesses and industry to be well-prepared for fire incidents. The stated goal is to minimize or, ideally, completely avoid damages caused by fires. Comprehensive fire protection includes a combination of preventive measures, such as fire detection systems and fire safety training, as well as active solutions in case of emergencies, such as fire extinguishing systems and smoke and heat extraction systems. The third area of Blue Vision A/S is energy-saving systems. Here, the company offers solutions and technologies to reduce the energy consumption of businesses and households. This not only protects the environment but also reduces energy costs and increases energy efficiency. The company offers a wide range of systems and technologies that can be selected and installed according to the customer's needs. Other services provided by Blue Vision A/S include a 24-hour hotline, which is available to customers in case of emergencies. The company focuses on customer satisfaction and high service quality. It only works with high-quality products and has an experienced team of experts who are constantly being further trained. The company offers its services not only in Denmark but also in other European countries. Customers therefore benefit from international experience that the company has gained since its founding in 1998. The business model of Blue Vision A/S is based on diversification and a broad customer base. It is designed to create high value for businesses and individuals and offers its customers specific solutions tailored to their needs. The company is thus in a good position to achieve further growth and success.

The expected revenue of Pharma Equity Group A/S is 10.20 M DKK. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Pharma Equity Group A/S is 24.55 M DKK. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Pharma Equity Group A/S is currently 4.44. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Pharma Equity Group A/S stock.

The price-to-sales ratio (P/S) of Pharma Equity Group A/S is currently 10.70. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Pharma Equity Group A/S stock.

The Eulerpool Quality Score for Pharma Equity Group A/S is 1/10.

The ISIN of Pharma Equity Group A/S is DK0061155009. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Pharma Equity Group A/S is A2PUQT. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Pharma Equity Group A/S is PEG.CO. The ticker symbol is used to trade Pharma Equity Group A/S shares on the stock exchange.